BRCA (Breast cancer early onset)

P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027

In our study, we showed that simple yet biologically meaningful similarity measures like Cosine Similarity can outperform more complex techniques in accuracy, consistency, and clarity. This insight sets the stage for building more effective and interpretable graph-based models to support precision medicine.

These findings will help guide the development of eribulin-based neoadjuvant chemotherapy for selected TNBC patients. Our exploratory analysis of LC and NLR results may help inform clinical prediction models for eribulin-treated patients.

PRS assessment identified four PRSs with good discriminatory power (AUC > 0.690), with PGS003738 showing the highest performance (AUC = 0.702, top decile OR = 3.57). These findings highlight the need for population-specific genetic studies to improve breast cancer risk stratification in Arab populations.

This work provides a modular, reproducible, and interpretable framework for survival modeling in high-dimensional genomics. By combining classical statistical models with biological structure, it offers a transparent approach for biomarker discovery and precision oncology.

Most PARPi responders had alterations in HRR genes, particularly BRCA2, although some responders lacked known biomarkers associated with PARPi response. Our findings in this real-world data set support HRR gene testing for PARPi use in mCRPC and highlight the need for novel genome-wide biomarkers for patient selection.

Abemaciclib (monarchE) has demonstrated sustained improvements in invasive disease-free survival (IDFS), distant relapse-free survival (DRFS), and a statistically significant overall survival (OS) benefit at 7 years. Ribociclib (NATALEE) demonstrated statistically significant IDFS improvement across a broader clinical risk spectrum, including selected node-negative disease.However, these advances must be considered in the context of distinct toxicity, treatment burden, and substantial additional healthcare system costs. Although emerging evidence supports treatment intensification with CDK4/6 inhibitors in certain settings, uncertainty persists regarding which patient subgroups derive sufficient benefit to justify routine use from both a clinical and health-economic perspective.Further clarification is expected from ongoing randomized studies and real-world evidence, as this paper aims to provide a structured, evidence-based overview of the current standard of knowledge and to support Austrian breast cancer specialists in navigating treatment decisions regarding adjuvant CDK4/6 inhibitor use.

P1/2, N=442, Recruiting, Artios Pharma Ltd | Trial completion date: Dec 2026 --> Dec 2027

Here we analyze the evolving landscape of PARPi-based combination therapies through three conceptual lenses: mechanistic interrogation of synthetic lethal networks beyond canonical HRR defects, clinical translation of combinatorial vulnerabilities across tumor lineages, and critical appraisal of therapeutic ceilings through pharmacodynamic biomarkers. By bridging preclinical rationales with clinical validation data, we propose a translational framework to optimize combinatorial therapeutic indices, ultimately guiding rational clinical development and precision medicine implementation.

Further research into ferroptosis-based therapy for TNBC, immunogenic cell death (ICD) with nano-enabled immunotherapy, multimodal nanotheranostics for TNBC, and clinical translation of NT in TNBC studies is recommended to advance nanotechnology research in TNBC.

We also noted contrasts in nucleotide-excision-repair involvement (ERCC5/POLE mutations vs ERCC1/CUL4A CNV gains), and mutational-signature analysis indicated greater MMR- and AID/POLE-associated exposures in the White cohort. To our knowledge, this study provides an initial multi-omics characterization of breast tumors from Native American women and offers a resource and hypotheses for larger, harmonized studies to assess prognostic and therapeutic relevance.

P=N/A, N=300, Not yet recruiting, M.D. Anderson Cancer Center